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The Mental Welfare Commission for Scotland has, as part
of its remit, a responsibility to develop good practice
guidelines in respect of medical treatment in the setting of
mental disorders. (These include people with dementia,
intellectual disability, severe and enduring mental illness
or brain injury which has led to a loss or impairment of
capacity.) The process undertaken to develop such a
guideline for the administration of covert medication to
people with mental disorder is described. The process
involved consultation with representatives of service
users, carers and providers of services for people with
mental disorder as well as professionals involved in their
care. Within the current framework of Scots law case
examples and evidence from research and existing practice
guidance also informed the process [1,2]. The content of
the guideline will be detailed using a case study approach.
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